All articles by Allie Nawrat

1. GSK’s belantamab mafodotin performs well in refractory multiple myeloma

   GlaxoSmithKline (GSK) has announced its experimental drug belantamab mafodotin (GSK2857916) has met its primary endpoint in the DREAMM-2 trial of…
   Read More…

   23 Aug
2. Medidata CEO Tarek Sherif on the past and future of pharma R&D

   After 20 years since its founding, clinical development-focused Medidata announced in June this year that it had been acquired by…
   Read More…

   22 Aug
3. Prescription dread: measuring psychiatric drugs against the alternatives

   In November, the Organisation for Economic Co-operation and Development estimated that mental health diagnosis and prescription drugs cost the UK…
   Read More…

   22 Aug
4. NHS England expands funding of Roche’s Hemlibra for haemophilia A

   NHS England has announced it will reimburse Hemlibra (emicizumab) for severe congenital haemophilia A patients without clotting protein factor VIII…
   Read More…

   22 Aug
5. Buyers’ clubs: the first step toward universal UK access to Orkambi?

   Due to the known success of buyers’ clubs in gaining emergency access to HIV/AIDS and Hepatitis C medicines, parents of…
   Read More…

   21 Aug
6. AstraZeneca’s Imfinzi fails to meet endpoint in Stage IV NSCLC

   AstraZeneca has announced that Imfinzi (durvalumab), combined with tremelimumab, failed to achieve its primary endpoint in the Phase III NEPTUNE…
   Read More…

   21 Aug
7. Real world data: how can it improve clinical trial outcomes?

   Real world data is information captured as a “by-product of everyday patient care”, in the words of Elsevier’s vice-president of…
   Read More…

   20 Aug
8. AstraZeneca’s diabetes drug Farxiga performs well in heart failure patients

   AstraZeneca has announced that Farxiga (dapagliflozin) met its primary endpoint in heart failure-focused Phase III DAPA-HF trial of patients with…
   Read More…

   20 Aug
9. Tackling Ebola: drugs alone cannot end the outbreak

   Ebola, described by Médecins Sans Frontières (MSF) as ‘one of the world’s deadliest diseases’, is currently rampaging across the Democratic…
   Read More…

   19 Aug
10. Researchers develop compound to reduce injury due to heart attacks

    Researchers from Virginia Tech University (VT) have developed a variant of the compound alphaCT1, which can improve heart attack recovery…
    Read More…

    19 Aug